- Home
- IFRX vs ALVOW Comparison
IFRX vs ALVOW Comparison
Compare IFRX & ALVOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- ALVOW
- Stock Information
- Founded
- IFRX 2007
- ALVOW N/A
- Country
- IFRX Germany
- ALVOW Luxembourg
- Employees
- IFRX N/A
- ALVOW 999
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- ALVOW Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IFRX Health Care
- ALVOW Health Care
- Exchange
- IFRX Nasdaq
- ALVOW Nasdaq
- Market Cap
- IFRX 120.1M
- ALVOW N/A
- IPO Year
- IFRX 2017
- ALVOW N/A
- Fundamental
- Price
- IFRX $2.06
- ALVOW $3.06
- Analyst Decision
- IFRX Strong Buy
- ALVOW
- Analyst Count
- IFRX 1
- ALVOW 0
- Target Price
- IFRX $8.00
- ALVOW N/A
- AVG Volume (30 Days)
- IFRX 266.7K
- ALVOW N/A
- Earning Date
- IFRX 11-08-2024
- ALVOW N/A
- Dividend Yield
- IFRX N/A
- ALVOW N/A
- EPS Growth
- IFRX N/A
- ALVOW N/A
- EPS
- IFRX N/A
- ALVOW N/A
- Revenue
- IFRX $187,930.00
- ALVOW N/A
- Revenue This Year
- IFRX $311.47
- ALVOW N/A
- Revenue Next Year
- IFRX $227.11
- ALVOW N/A
- P/E Ratio
- IFRX N/A
- ALVOW N/A
- Revenue Growth
- IFRX 177.12
- ALVOW N/A
- 52 Week Low
- IFRX $1.17
- ALVOW N/A
- 52 Week High
- IFRX $2.44
- ALVOW N/A
- Technical
- Relative Strength Index (RSI)
- IFRX 67.23
- ALVOW N/A
- Support Level
- IFRX $1.51
- ALVOW N/A
- Resistance Level
- IFRX $2.15
- ALVOW N/A
- Average True Range (ATR)
- IFRX 0.24
- ALVOW 0.00
- MACD
- IFRX 0.05
- ALVOW 0.00
- Stochastic Oscillator
- IFRX 60.42
- ALVOW 0.00
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About ALVOW Alvotech Warrant
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.